Authors

Matthew JL Hare

MBBS, BMedSc, FRACP, Endocrinologist, Department of Endocrinology, Royal Darwin Hospital, NT; Menzies School of Health Research, Charles Darwin University, NT


Current evidence and practical guidance for the use of sodium–glucose co-transporter-2 inhibitors in type 2 diabetes

Sodium–glucose co-transporter-2 inhibitors are becoming a cornerstone of therapy for type 2 diabetes, kidney disease and heart failure.